Plasma Levels of High Molecular Weight Adiponectin are Associated with Cardiometabolic Risks in Patients with Hypertension.
- Author:
Hye Kyung CHUNG
1
;
Min Jeong SHIN
Author Information
1. Department of Nutrition Services, Youngdong Severance Hospital, Yonsei University College of Medicine, Seoul 135-720, Korea.
- Publication Type:Original Article
- Keywords:
high molecular weight adiponectin;
cardiometabolic risk;
hypertension;
C-reactive protein;
inflammation
- MeSH:
Adiponectin;
Body Fat Distribution;
Body Mass Index;
C-Reactive Protein;
Cardiovascular Diseases;
Cross-Sectional Studies;
Dyslipidemias;
Enzyme-Linked Immunosorbent Assay;
Fasting;
Glucose;
Homeostasis;
Humans;
Hypertension;
Inflammation;
Insulin;
Insulin Resistance;
Intercellular Adhesion Molecule-1;
Interleukin-6;
Linear Models;
Molecular Weight;
Plasma;
Smoke;
Smoking;
Tumor Necrosis Factor-alpha;
Waist Circumference
- From:The Korean Journal of Nutrition
2008;41(8):733-741
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In the present study, we comprehensively examined the associations of plasma levels of total adiponectin and high molecular weight (HMW) adiponectin with the features of cardiometabolic risks including body fat distribution, dyslipidemia, insulin resistance and inflammatory markers in a cross-sectional study of 110 treated hypertensive patients. Blood lipid profiles, high sensitivity C-reactive protein (hsCRP) and homeostasis model assessment of insulin resistance (HOMA-IR) derived from fasting glucose and insulin concentrations were determined. Plasma levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6) and intercellular adhesion molecule-1 (ICAM-1) were analyzed using ELISA. The results showed that plasma levels of HMW-adiponectin were negatively associated with body mass index (BMI, r = -0.203, p < 0.05) and waist circumference (r = -0.307, p < 0.01), which was not shown in total adiponectin. Plasma levels of HMW-adiponectin were negatively associated with triglyceride (r = -0.223, p < 0.05) and positively associated with HDL-cholesterol (r = 0.228, p < 0.05). Plasma levels of adiponectin were positively associated with HDL-cholesterol (r = 0.224, p < 0.05). Plasma levels of HMW-adiponectin were negatively associated with hsCRP (r = -0.276, p < 0.01) and IL-6 (r = -0.272, p < 0.01). In addition, there were weak associations between plasma levels of HMWadiponectin and TNF-alpha (r = -0.163, p = 0.07) and ICAM-1 (r = -0.158, p = 0.09). However, there were no significant associations of total adiponectin with inflammatory markers except hsCRP (r = -0.203, p < 0.05). Stepwise multiple linear regression analysis showed that only plasma levels of HMW-adiponectin was an independent factor influencing serum levels of hsCRP, a marker of systemic low grade inflammation, after adjusting for age, gender, BMI, waist circumference, alcohol intake, smoking status, blood lipids, total adiponectin and drug use (p < 0.01). These results suggest that HMW-adiponectin, rather than total adiponectin, is likely to be closely associated with the features of cardiometabolic risks in treated hypertensive patients and might be effective biomarker for the prediction of cardiovascular disease.
